Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

ClinicalTrials.gov ID: NCT04391049

Public ClinicalTrials.gov record NCT04391049. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

Study identification

NCT ID: NCT04391049
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: NRG Oncology; Other
Enrollment: 16 participants

Conditions and interventions

Conditions

Interventions

Carboplatin Drug
Paclitaxel Drug
Radiation Therapy Radiation
Telomerase-specific Type 5 Adenovirus OBP-301 Biological

Drug · Radiation · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2021
Primary completion: Oct 5, 2024
Completion: Sep 30, 2026
Last update posted: Jan 29, 2026

2021 – 2026

United States locations

U.S. sites: 17
U.S. states: 8
U.S. cities: 17

Facility	City	State	ZIP	Site status
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
City of Hope South Pasadena	South Pasadena	California	91030	—
City of Hope Upland	Upland	California	91786	—
Moffitt Cancer Center	Tampa	Florida	33612	—
University of Kansas Clinical Research Center	Fairway	Kansas	66205	—
University of Kansas Cancer Center	Kansas City	Kansas	66160	—
University of Kansas Hospital-Westwood Cancer Center	Westwood	Kansas	66205	—
Massachusetts General Hospital Cancer Center	Boston	Massachusetts	02114	—
Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey	07920	—
Memorial Sloan Kettering Monmouth	Middletown	New Jersey	07748	—
Memorial Sloan Kettering Bergen	Montvale	New Jersey	07645	—
Memorial Sloan Kettering Commack	Commack	New York	11725	—
Memorial Sloan Kettering Westchester	Harrison	New York	10604	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Memorial Sloan Kettering Nassau	Uniondale	New York	11553	—
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	—
M D Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04391049, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 29, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04391049 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →